Treatments for COVID-19: emerging drugs against the coronavirus
Keywords:
COVID-19 , Reserpine , COPB2Abstract
N/A
References
Potì F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for COVID-19: emerging drugs against the coronavirus. Acta Bio-Medica Atenei Parm. 2020 May 11;91(2):118–36.
Duarte RRR, Copertino Jr. DC, Iñiguez LP, Marston JL, Nixon DF, Powell TR. Repurposing FDA-Approved Drugs for COVID-19 Using a Data-Driven Approach. 2020 Apr 21 [cited 2020 Jun 2]; Available from: https://chemrxiv.org/articles/Repurposing_FDA-Approved_Drugs_for_COVID-19_Using_a_Data-Driven_Approach/12148764
Wilde AH de, Wannee KF, Scholte FEM et al. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. J Virol. 2015 Aug 15;89(16):8318–33.
Avchaciov K, Burmistrova O, Fedichev PO. AI for the repurposing of approved or investigational drugs against COVID-19. Res Gate Doi Doi. 2020;10.
Wu C-Y, Jan J-T, Ma S-H et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci. 2004 Jul 6;101(27):10012–7.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
